knowledge -WSS

knowledge

author：fashion 2025-10-01 10:52:12 - browse：15241

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Lilly's Alzheimer's drug donanemab backed by FDA advisers

focus

WSS

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

SEC charges former device maker CEO with $41 million fraud

The system is set up to fail children with medical complexity

Editas, Vertex strike deal on CRISPR

In Spain, a hospital brews its own CAR

California wildfire smoke linked to 52,000 early deaths, study says

hotspot

knowledge

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readers discuss the intersection of pregnancy and addiction

Peter Hotez and the public health issue of online harassment

Lilly's Alzheimer's drug donanemab backed by FDA advisers

New air purifier tech could be key to improving indoor air quality

CRISPR gene editing developments we’re watching in 2024

Peter Hotez and the public health issue of online harassment

Readers discuss the intersection of pregnancy and addiction

Bright Health sells Medicare Advantage business to Molina

Health care court cases: Humana, Sutter, Novant

focus

Coercive sterilizations revealed by STAT prompt outrage

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Keeping primary care docs in field isn't impossible, says AAFP CEO

Teladoc has a new CEO, but challenges remain the same

The system is set up to fail children with medical complexity

Teladoc has a new CEO, but challenges remain the same

hotspot

hotspot

focus

focus